648 related articles for article (PubMed ID: 33374173)
1. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.
Ambrosius W; Michalak S; Kozubski W; Kalinowska A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173
[TBL] [Abstract][Full Text] [Related]
2. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
3. MOG antibody-associated encephalomyelitis/encephalitis.
Salama S; Khan M; Pardo S; Izbudak I; Levy M
Mult Scler; 2019 Oct; 25(11):1427-1433. PubMed ID: 30907249
[TBL] [Abstract][Full Text] [Related]
4. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
[TBL] [Abstract][Full Text] [Related]
5. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
[TBL] [Abstract][Full Text] [Related]
6. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
7. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
Ramanathan S; Mohammad S; Tantsis E; Nguyen TK; Merheb V; Fung VSC; White OB; Broadley S; Lechner-Scott J; Vucic S; Henderson APD; Barnett MH; Reddel SW; Brilot F; Dale RC;
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):127-137. PubMed ID: 29142145
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
[TBL] [Abstract][Full Text] [Related]
9. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
[TBL] [Abstract][Full Text] [Related]
10. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
Chen JJ; Bhatti MT
Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders.
Konuskan B; Yildirim M; Gocmen R; Okur TD; Polat I; Kilic H; Saltik S; Ozturk Z; Gucuyener K; Altunbasak S; Celik T; Kose G; Yilmaz A; Komur M; Kayilioglu H; Anlar B
Mult Scler Relat Disord; 2018 Nov; 26():1-7. PubMed ID: 30212767
[TBL] [Abstract][Full Text] [Related]
12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid eosinophils in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
Kornbluh AB; Campano VM; Har C; Dwivedi P; Suslovic W; Sepeta L; Kahn I
Mult Scler Relat Disord; 2024 May; 85():105526. PubMed ID: 38489945
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
Jarius S; Lechner C; Wendel EM; Baumann M; Breu M; Schimmel M; Karenfort M; Marina AD; Merkenschlager A; Thiels C; Blaschek A; Salandin M; Leiz S; Leypoldt F; Pschibul A; Hackenberg A; Hahn A; Syrbe S; Strautmanis J; Häusler M; Krieg P; Eisenkölbl A; Stoffels J; Eckenweiler M; Ayzenberg I; Haas J; Höftberger R; Kleiter I; Korporal-Kuhnke M; Ringelstein M; Ruprecht K; Siebert N; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; Rostásy K;
J Neuroinflammation; 2020 Sep; 17(1):262. PubMed ID: 32883358
[TBL] [Abstract][Full Text] [Related]
15. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.
Armangue T; Olivé-Cirera G; Martínez-Hernandez E; Sepulveda M; Ruiz-Garcia R; Muñoz-Batista M; Ariño H; González-Álvarez V; Felipe-Rucián A; Jesús Martínez-González M; Cantarín-Extremera V; Concepción Miranda-Herrero M; Monge-Galindo L; Tomás-Vila M; Miravet E; Málaga I; Arrambide G; Auger C; Tintoré M; Montalban X; Vanderver A; Graus F; Saiz A; Dalmau J;
Lancet Neurol; 2020 Mar; 19(3):234-246. PubMed ID: 32057303
[TBL] [Abstract][Full Text] [Related]
16. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases.
Baumann M; Hennes EM; Schanda K; Karenfort M; Kornek B; Seidl R; Diepold K; Lauffer H; Marquardt I; Strautmanis J; Syrbe S; Vieker S; Höftberger R; Reindl M; Rostásy K
Mult Scler; 2016 Dec; 22(14):1821-1829. PubMed ID: 26869530
[TBL] [Abstract][Full Text] [Related]
17. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.
Sechi E; Cacciaguerra L; Chen JJ; Mariotto S; Fadda G; Dinoto A; Lopez-Chiriboga AS; Pittock SJ; Flanagan EP
Front Neurol; 2022; 13():885218. PubMed ID: 35785363
[TBL] [Abstract][Full Text] [Related]
18. E.U. paediatric MOG consortium consensus: Part 2 - Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostásy K;
Eur J Paediatr Neurol; 2020 Nov; 29():14-21. PubMed ID: 33158737
[TBL] [Abstract][Full Text] [Related]
19. Clinical and radiographic features of a cohort of adult and pediatric subjects in the Pacific Northwest with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Martin K; Srikanth P; Kanwar A; Falardeau J; Pettersson D; Yadav V
Mult Scler Relat Disord; 2024 Jan; 81():105130. PubMed ID: 37979410
[TBL] [Abstract][Full Text] [Related]
20. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.
Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M
Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
